Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
1.010
-0.010 (-0.98%)
Nov 21, 2024, 10:38 AM EST - Market open
Company Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.
The company was founded in 2010 and is based in Glen Allen, Virginia.
Adial Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jul 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Cary Claiborne |
Contact Details
Address: 4870 Sadler Road, Suite 300 Glen Allen, Virginia 23060 United States | |
| Phone | 804 487 8196 |
| Website | adialpharma.com |
Stock Details
| Ticker Symbol | ADIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513525 |
| CUSIP Number | 00688A106 |
| ISIN Number | US00688A2050 |
| Employer ID | 80-0667150 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cary John Claiborne MBA | Chief Executive Officer, President and Director |
| Joseph A. M. Truluck M.B.A., MBA | Chief Financial Officer, Treasurer and Secretary |
| John R. Martin J.D. | Chief Legal Officer |
| Andrew Taubman | Vice President of Corporate Development |
| Catherine Fratila | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 5, 2024 | 8-K | Current Report |
| Sep 30, 2024 | ARS | Filing |
| Sep 27, 2024 | DEF 14A | Other definitive proxy statements |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | 8-K | Current Report |